TABLE 6.

Influences of WT and cross-reactivity-reduced JEV and WNV VLPs on the performances of MAC- and GAC-ELISAsa

Disease panelAssayPerformance
AntigenSerum dilutionSensitivity (%)95% CISpecificity (%)95% CILikelihood ratio
JEVMAC-ELISA
JEV-WT1:40010079.4-100.041.2729.01-54.381.7
1:4,00010079.4-100.063.4950.41-75.272.74
JEV-KD1:40010079.41-100.063.6447.77-77.592.75
1:4,00010079.41-100.095.4584.53-99.4422
GAC-ELISA
JEV-WT1:4,00086.3672.65-94.836.250.1581-30.230.92
JEV-KD1:4,00087.561.65-98.4545.4530.39-61.151.6
WNVMAC-ELISA
WNV-WT1:40010083.89-100.017.248.590-29.431.21
1:4,00010078.20-100.057.7842.15-72.342.37
WNV-RH1:40010083.89-100.052.6338.97-66.022.11
1:4,00010078.20-100.091.1178.78-97.5211.25
GAC-ELISA
WNV-WT1:4,00010078.20-100.017.248.590-29.431.21
WNV-RH1:4,00010078.20-100.051.7238.22-65.052.07
  • a Influence on abilities to distinguish JEV and WNV serum panels (disease panels), respectively, from other arbovirus-infected serum panels (control panels) using the positive-cutoff criterion (P/N ≥ 3) as the evidence of infection.